Healthcare Sales & Marketing Network News: TD-1792

Searching News Database: TD-1792

HSMN NewsFeed - 5 Mar 2008
FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Dec 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Sep 2007
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 31 Jul 2007
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jul 2006
Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
Biopharmaceuticals

Return to NewsFeed

Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 1 additional stories matching:
TD-1792
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.